Trust Signals
Key Takeaways
- 5-amino-1MQ is a small-molecule NNMT inhibitor, not a peptide, despite how it is marketed in compounding channels.
- The strongest published evidence is a 2019 rodent study (Neelakantan et al., Cell Chemical Biology) showing fat mass reduction and improved insulin sensitivity in diet-induced obese mice.
- Zero published human RCTs exist as of mid-2026. Every human benefit claim is extrapolated from animal or cell data.
- The mechanistic pathway through SAM, NAD+ precursors, and adipocyte gene expression is scientifically coherent but does not constitute proof of human efficacy.
- Compared to approved GLP-1 agonists, 5-amino-1MQ loses decisively on evidence quality. Its potential niche is as an adjunct or investigational option under clinical supervision.
Does 5-Amino-1MQ Work? (Direct Answer)
Does 5-amino-1MQ work? In rodents with diet-induced obesity, yes, it demonstrably reduced fat mass and improved metabolic markers through NNMT inhibition. In humans, the honest answer is: unknown. The mechanism is real, the animal signal is reproducible, and human trials are absent. Confidence that it works in people is low by any evidence-grading standard.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is 5-amino-1MQ and is it actually a peptide?
- What does the best available evidence actually show?
- How does 5-amino-1MQ work? Mechanism with specific numbers
- Evidence ledger: every major claim graded
- What most pages get wrong about 5-amino-1MQ
- Why formulation and purity matter more than the dose
- Honest head-to-head: 5-amino-1MQ vs. real alternatives
- How to read a product or COA for 5-amino-1MQ
- FAQ
- Sources
- Footer Disclaimers
What Is 5-Amino-1MQ and Is It Actually a Peptide?
5-amino-1MQ stands for 5-amino-1-methylquinolinium. It is a synthetic, small-molecule quaternary amine with a molecular weight of approximately 174 daltons. Peptides are chains of amino acids linked by peptide bonds. 5-amino-1MQ is neither. It is grouped with research peptides in commercial wellness markets because it is sold through similar compounding pharmacy and research-chemical channels, not because of any structural similarity.
Its target is the enzyme nicotinamide N-methyltransferase, commonly abbreviated NNMT. NNMT is expressed primarily in adipose tissue, liver, and skeletal muscle and catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing S-adenosylhomocysteine (SAH) and 1-methylnicotinamide as byproducts. 5-amino-1MQ is a competitive inhibitor of this reaction.
What Does the Best Available Evidence Actually Show?
The foundational published study is Neelakantan et al. (2019), published in Cell Chemical Biology. That study administered 5-amino-1MQ to diet-induced obese mice. The treated animals showed reductions in body weight and fat mass relative to controls, improved insulin sensitivity on glucose tolerance testing, and gene expression changes in adipose tissue consistent with reduced lipid accumulation. The authors reported no significant acute toxicity signals over their study period.
Supportive mechanistic work comes from earlier NNMT biology research: studies by Kraus et al. (published in Nature Medicine, 2014) demonstrated that NNMT knockdown in mice reduced fat mass and improved metabolic health, establishing the target's validity before 5-amino-1MQ entered the picture. That earlier genetic validation is important context. It means the target is credible, not just the compound.
How Does 5-Amino-1MQ Work? Mechanism with Specific Numbers
NNMT consumes SAM, the body's universal methyl donor, at a rate that in obese adipose tissue is substantially elevated compared to lean tissue. When NNMT is overactive, two downstream consequences follow. First, the SAM-to-SAH ratio falls, reducing the methylation potential available for other cellular processes including histone and DNA methylation that regulate metabolic gene expression. Second, nicotinamide is diverted away from the NAD+ biosynthesis pathway because it is being methylated and excreted rather than recycled via the Preiss-Handler pathway.
By competitively inhibiting NNMT, 5-amino-1MQ is hypothesized to restore the SAM-to-SAH ratio and redirect nicotinamide toward NAD+ synthesis. In the Neelakantan 2019 study, the inhibitor had an IC50 (concentration for 50 percent enzyme inhibition) in the low micromolar range in biochemical assays, a potency range considered pharmacologically meaningful for enzyme inhibitors.
What this mechanism does NOT prove: demonstrating that NNMT inhibition raises the SAM-to-SAH ratio in a cell or mouse does not prove that the same shift occurs in human adipose tissue at orally delivered doses, nor does it prove that any resulting gene expression change translates to clinically meaningful fat loss in people with different backgrounds, comorbidities, and diets.
Evidence Ledger: Every Major Claim Graded
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| 5-amino-1MQ inhibits NNMT enzyme activity | Biochemical assay (in vitro) | Inhibitory, low micromolar IC50 | High (mechanism confirmed in vitro) |
| NNMT inhibition reduces fat mass in obese mice | Rodent RCT analog (Neelakantan 2019) | Positive, statistically significant in that study | Moderate (single model, single study) |
| NNMT knockdown improves metabolic health in mice | Rodent genetic model (Kraus et al. 2014) | Positive | Moderate (genetic model, not drug inhibition) |
| 5-amino-1MQ raises NAD+ in humans | Mechanism only (extrapolated) | Directionally plausible | Very Low (no human measurement) |
| 5-amino-1MQ reduces body fat in humans | No controlled human data | Unknown | Very Low |
| 5-amino-1MQ preserves or increases muscle mass | Speculative extrapolation from metabolic effects | Unknown | Very Low |
| 5-amino-1MQ is safe in humans at compounded doses | No human safety trial data | Unknown | Very Low |
What Most Pages Get Wrong About 5-Amino-1MQ
Most wellness and peptide vendor pages commit three errors that misrepresent the evidence.
Error 1: Treating rodent efficacy as human efficacy. A compound that works in diet-induced obese mice has approximately a 90 percent failure rate when advanced to human clinical trials, across all therapeutic categories. NNMT biology may differ between species in adipose distribution, expression levels, and compensatory pathways. The rodent finding is a promising hypothesis, not a proven treatment.
Error 2: Conflating the NNMT target's validation with the compound's validation. Kraus et al. 2014 used genetic knockdown of NNMT, not 5-amino-1MQ. That study validates the target. It does not validate this specific inhibitor's oral bioavailability, tissue distribution, or selectivity in humans. These are separate questions.
Error 3: Omitting the methylation risk. NNMT consumes SAM, but so does every other methyltransferase in the body. By raising SAM availability through NNMT inhibition, you theoretically increase substrate for other methylation reactions, including those involved in epigenetic regulation of gene expression broadly. Whether that is beneficial, neutral, or harmful in the long run is not characterized. Pages that frame NNMT inhibition as purely positive omit this unknown.
Why Formulation and Purity Matter More Than the Dose
5-amino-1MQ is a quaternary amine salt. It is moisture-sensitive and can degrade on exposure to humidity and light. Unlike injectable peptides that arrive lyophilized in sealed vials, 5-amino-1MQ is frequently compounded into oral capsules. Capsule manufacturing quality varies enormously between compounding pharmacies, and there is no FDA-approved reference formulation to benchmark against.
Impurities from synthesis matter specifically for this compound because quinolinium derivatives can carry genotoxic precursors depending on the synthetic route. A certificate of analysis (COA) from a reputable third-party laboratory should show purity above 98 percent by HPLC, with a report of absence of residual solvents and heavy metals. A COA signed only by the vendor's internal lab is substantially less reliable than one from an independent, ISO 17025-accredited lab.
Stability in capsule form is not publicly characterized in peer-reviewed literature. As a practical matter, store capsules sealed with a desiccant, away from heat and light, and respect the beyond-use date assigned by the compounding pharmacy. A degraded product will not inhibit NNMT at the intended concentration and may deliver unknown breakdown products.
Honest Head-to-Head: 5-Amino-1MQ vs. Real Alternatives
| Compound | Mechanism | Best Human Evidence | Typical Weight Effect (Human Data) | Known Safety Profile | Where 5-Amino-1MQ Loses |
|---|---|---|---|---|---|
| 5-Amino-1MQ | NNMT inhibition | None (animal only) | Unknown in humans | Not characterized in humans | Everywhere that evidence matters |
| Semaglutide (GLP-1 RA) | GLP-1 receptor agonism, appetite suppression | Multiple large RCTs (STEP trials, thousands of participants) | Roughly 10 to 15 percent body weight reduction at 68 weeks | Well-characterized; GI side effects common | 5-amino-1MQ cannot compete on evidence |
| Tirzepatide (GLP-1/GIP RA) | Dual incretin receptor agonism | SURMOUNT trials (large RCTs) | Up to roughly 20 percent body weight reduction | Well-characterized; similar GI profile | 5-amino-1MQ cannot compete on evidence |
| NMN / NR (NAD+ precursors) | Direct NAD+ precursor supplementation | Small human trials; metabolic effects modest | No meaningful weight effect in trials to date | Appears safe in short-term studies | 5-amino-1MQ possibly more targeted on NNMT; NMN has more human data overall |
| AOD-9604 (peptide comparator) | GH fragment, lipolysis signaling | One phase IIb trial; failed primary endpoint | No significant effect vs. placebo in pivotal trial | Limited; no serious signals in trials | Both are low-evidence; AOD-9604 has more human trial data, but those data showed failure |
How to Read a Product or COA for 5-Amino-1MQ
Identity confirmation: The COA should show an HPLC chromatogram or mass spectrometry result confirming the molecular weight of approximately 174 Da and the correct UV absorption profile for a quinolinium compound. If the COA shows only a visual or melting point test, that is insufficient.
Purity threshold: Seek 98 percent or higher by area under curve on HPLC. Anything below 95 percent from a supplier marketing this as a research compound should prompt questions about the synthetic process.
Residual solvents: Quinolinium compounds can be synthesized using solvents such as acetonitrile or methanol. The COA should report residual solvent levels compliant with ICH Q3C guidelines.
Dose verification: Compounded capsules should include a potency test showing actual milligram content per capsule. Label claim and actual content can differ substantially in compounding contexts without independent assay verification.
What a degraded product looks like: 5-amino-1MQ is typically a pale yellow to off-white powder. Browning, clumping from moisture exposure, or a sharp chemical odor may indicate degradation or contamination, though visual inspection alone cannot confirm purity.
FAQ
Does 5-amino-1MQ work for fat loss?
In mouse models, 5-amino-1MQ produced meaningful reductions in fat mass and improved metabolic markers by inhibiting NNMT and raising SAM-to-SAH ratios. No human RCT data exist yet, so applying those results directly to people requires caution. The mechanism is plausible and the animal signal is real, but human efficacy is unproven.
What is 5-amino-1MQ and how does it work?
5-amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). By blocking NNMT, it reduces consumption of SAM and is thought to raise NAD+ precursor availability, shift adipocyte gene expression toward leanness, and reduce lipid accumulation.
Has 5-amino-1MQ been tested in humans?
As of mid-2026, no published human randomized controlled trials exist for 5-amino-1MQ. Evidence comes from cell culture and rodent studies. It is classified as a research compound, not an approved drug or regulated supplement.
What did the key animal study on 5-amino-1MQ show?
A study by Neelakantan et al. (published in Cell Chemical Biology, 2019) showed that 5-amino-1MQ administered to diet-induced obese mice reduced body weight and fat mass, improved insulin sensitivity, and altered adipocyte gene expression consistent with reduced lipid storage, without significant toxicity signals in that study duration.
Is 5-amino-1MQ a peptide?
No. 5-amino-1MQ is a small-molecule quaternary amine, not a peptide. It is commonly grouped with research peptides in the compounding and wellness market for commercial reasons, but it has a fundamentally different structure and pharmacology than peptide compounds.
What are the known side effects of 5-amino-1MQ?
Human safety data are absent. Animal studies used in the primary research did not report significant acute toxicity at doses tested, but chronic safety, off-target effects on methylation pathways, and long-term cardiovascular or oncological risks have not been characterized in humans. This is a major knowledge gap.
How does 5-amino-1MQ compare to semaglutide or tirzepatide for weight loss?
GLP-1 receptor agonists like semaglutide have large, replicated human RCTs showing 10 to 15 percent body weight reduction. 5-amino-1MQ has only rodent data. On evidence quality alone, semaglutide wins decisively. 5-amino-1MQ may appeal as an adjunct or for those who cannot tolerate GLP-1 side effects, but the comparison is not yet meaningful scientifically.
What dose of 5-amino-1MQ is used in research?
The Neelakantan 2019 mouse study used specific oral doses in rodents. Any human-equivalent figure derived from body surface area scaling is an extrapolation, not a validated clinical dose. Human dosing protocols used in compounding contexts vary widely and are not validated by clinical trial data. Any specific human dose is currently empirical, not evidence-based.
Can you buy 5-amino-1MQ legally?
In the United States, 5-amino-1MQ is not FDA-approved as a drug or dietary supplement. It is sold as a research chemical or, in some cases, compounded by licensed pharmacies for specific patients under a practitioner prescription. Regulatory status varies by country. Purchasing from unverified sources carries contamination and dosing risks.
Does 5-amino-1MQ raise NAD+ levels?
Indirectly, possibly. NNMT consumes SAM and produces 1-methylnicotinamide as a byproduct, diverting nicotinamide from NAD+ synthesis. Inhibiting NNMT may redirect more nicotinamide toward NAD+ production. This is mechanistically plausible but has not been directly measured in human tissue with 5-amino-1MQ treatment.
How should 5-amino-1MQ be stored?
5-amino-1MQ is a small quaternary amine that is moisture-sensitive. Capsule or powder forms should be stored in a cool, dry, dark environment, ideally sealed with a desiccant. Exposure to humidity and light can accelerate degradation. Compounded formulations should follow the beyond-use dating on the label from the dispensing pharmacy.
Is 5-amino-1MQ worth trying?
That depends on your risk tolerance and clinical context. The mechanistic rationale is scientifically interesting and the animal data are promising, but the absence of human trials means you are accepting unknown risks for unproven benefits. A prescribing clinician who monitors metabolic markers can reduce but not eliminate that uncertainty.
Sources
- Neelakantan H, et al. "5-Amino-1-methylquinolinium as a highly selective inhibitor of nicotinamide N-methyltransferase (NNMT) reduces adipogenesis and promotes weight loss in diet-induced obese mice." Cell Chemical Biology. 2019. (Primary efficacy study cited throughout this page.)
- Kraus D, et al. "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity." Nature Medicine. 2014;20(4):400-406. (Genetic target validation study.)
- Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine. 2021;384:989-1002. (STEP 1 trial, semaglutide efficacy benchmark.)
- Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine. 2022;387:205-216. (SURMOUNT-1 trial, tirzepatide efficacy benchmark.)
- ICH Guideline Q3C on Residual Solvents. International Council for Harmonisation. Current version. (Referenced in COA/purity section.)
- Campagna R, et al. "NAD+ Metabolism in the aging process and age-related diseases." International Journal of Molecular Sciences. 2023;24(14):11770. (Background on NAD+ biosynthesis pathways.)
- Brachs S, et al. "Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice." Molecular Metabolism. 2016. (Contextual metabolic pathway reference.)
- Tran NL, et al. "Nicotinamide N-methyltransferase (NNMT) in health and disease." Frontiers in Endocrinology. 2021;12:706277. (NNMT biology review.)
Footer Disclaimers
Platform: FormBlends is an informational platform. Content on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Research Compound: 5-amino-1MQ is not approved by the FDA or any equivalent regulatory agency as a drug or dietary supplement. It is a research compound. Use outside of a supervised clinical or research context may carry uncharacterized risks.
Results: Individual results, if any, will vary. No outcomes described in animal or mechanistic studies are guaranteed to translate to any specific human outcome.
Trademark: All brand names and drug names referenced are the property of their respective owners. FormBlends has no affiliation with the manufacturers of semaglutide, tirzepatide, or any other named compound. References are for comparative and educational purposes only.